Texas hedge fund manager Kyle Bass has sought another inter partes review (IPR), this time to challenge a patent covering Pharmacyclics’ cancer drug Imbruvica (ibrutinib).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kyle Bass, Coalition for Affordable Drugs, inter partes review, Pharmacyclics, Imbruvica